Outset Medical will release 2024 financial results on February 19, followed by a conference call for discussion.
Quiver AI Summary
Outset Medical, Inc. announced that it will release its fourth quarter and full-year 2024 financial results after market close on February 19, 2025. Following the release, CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call at 2:00 p.m. Pacific time to discuss the results. Interested participants can register online to obtain dial-in information for the call. Outset Medical is known for its innovative Tablo® Hemodialysis System, which simplifies dialysis delivery by integrating water purification and on-demand dialysate production, thus enabling care across various settings.
Potential Positives
- Outset Medical is set to release its financial results for Q4 and full-year 2024, which could indicate positive growth following the launch of their innovative Tablo® Hemodialysis System.
- The upcoming conference call presents an opportunity for stakeholders to engage directly with the company's leadership, emphasizing transparency and communication regarding financial and operational performance.
- The Tablo® Hemodialysis System represents a significant technological advancement in dialysis, aiming to reduce costs and complexities, which could enhance market competitiveness and improve patient care.
Potential Negatives
- Outset Medical has not disclosed specific financial performance metrics, leaving stakeholders to speculate regarding the company's current financial health and performance in the competitive medical technology market.
- The upcoming conference call to discuss results may indicate that the company is facing challenges, as timing for such discussions can often correlate with critical financial disclosures.
FAQ
When will Outset Medical release its 2024 financial results?
Outset Medical will release its financial results for the fourth quarter and full-year 2024 after the close of trading on February 19, 2025.
Who will host the conference call for the financial results?
Leslie Trigg, Chair and CEO, and Nabeel Ahmed, CFO, will host the conference call to discuss financial and operating results.
How can I access the conference call?
Participants can register online to receive dial-in numbers and a unique PIN to join the conference call.
Is there a webcast available for the conference call?
Yes, a live and archived webcast will be available on the “Investors” section of the Outset website.
What technology does Outset Medical offer for dialysis?
Outset Medical offers the Tablo® Hemodialysis System, designed to reduce the cost and complexity of dialysis for patients and providers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OM Insider Trading Activity
$OM insiders have traded $OM stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $OM stock by insiders over the last 6 months:
- LESLIE TRIGG (Chair and CEO) has made 0 purchases and 7 sales selling 119,643 shares for an estimated $101,270.
- NABEEL AHMED (Chief Financial Officer) has made 0 purchases and 7 sales selling 73,346 shares for an estimated $60,025.
- JOHN L. BROTTEM (General Counsel) has made 0 purchases and 7 sales selling 61,208 shares for an estimated $50,062.
- MARC NASH (SVP Operations and R&D) has made 0 purchases and 8 sales selling 41,620 shares for an estimated $33,850.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OM Hedge Fund Activity
We have seen 21 institutional investors add shares of $OM stock to their portfolio, and 85 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERIPRISE FINANCIAL INC removed 3,389,927 shares (-65.2%) from their portfolio in Q3 2024, for an estimated $2,294,980
- JPMORGAN CHASE & CO removed 3,057,774 shares (-99.5%) from their portfolio in Q3 2024, for an estimated $2,070,112
- FMR LLC removed 2,923,144 shares (-38.0%) from their portfolio in Q3 2024, for an estimated $1,978,968
- MORGAN STANLEY removed 2,631,008 shares (-69.0%) from their portfolio in Q3 2024, for an estimated $1,781,192
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,538,859 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,041,807
- GSA CAPITAL PARTNERS LLP added 1,003,135 shares (+924.7%) to their portfolio in Q3 2024, for an estimated $679,122
- D. E. SHAW & CO., INC. removed 848,503 shares (-66.4%) from their portfolio in Q3 2024, for an estimated $574,436
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN JOSE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2024 after the close of trading on Wednesday, February 19, 2025.
On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, February 19, 2025. Those interested in joining the conference call may do so by
registering online
. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at
https://investors.outsetmedical.com/
.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Contact
Jim Mazzola
Investor Relations
[email protected]